AEGON ASSET MANAGEMENT UK Plc Cuts Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

AEGON ASSET MANAGEMENT UK Plc lowered its position in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 5.3% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 46,844 shares of the medical research company's stock after selling 2,621 shares during the period. AEGON ASSET MANAGEMENT UK Plc's holdings in Thermo Fisher Scientific were worth $23,313,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also modified their holdings of the company. Bernard Wealth Management Corp. purchased a new position in Thermo Fisher Scientific during the 4th quarter valued at $25,000. Barrett & Company Inc. purchased a new stake in shares of Thermo Fisher Scientific during the fourth quarter valued at $28,000. FPC Investment Advisory Inc. bought a new position in shares of Thermo Fisher Scientific in the fourth quarter worth about $28,000. Pillar Financial Advisors LLC bought a new stake in Thermo Fisher Scientific during the 4th quarter valued at about $29,000. Finally, Ameriflex Group Inc. bought a new position in Thermo Fisher Scientific in the 4th quarter worth about $30,000. Hedge funds and other institutional investors own 89.23% of the company's stock.

Thermo Fisher Scientific Stock Performance

NYSE:TMO traded down $5.78 during trading hours on Thursday, hitting $397.88. 2,501,958 shares of the company were exchanged, compared to its average volume of 2,341,638. The company's 50 day moving average price is $424.35 and its 200-day moving average price is $497.38. The stock has a market capitalization of $150.20 billion, a price-to-earnings ratio of 24.07, a PEG ratio of 2.99 and a beta of 0.82. Thermo Fisher Scientific Inc. has a 52-week low of $390.49 and a 52-week high of $627.88. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.66 and a quick ratio of 1.29.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its earnings results on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $5.10 by $0.05. The company had revenue of $10.36 billion during the quarter, compared to analyst estimates of $10.23 billion. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. The firm's quarterly revenue was up .2% on a year-over-year basis. During the same quarter last year, the business posted $5.11 EPS. As a group, research analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, July 15th. Shareholders of record on Friday, June 13th will be given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 0.43%. The ex-dividend date of this dividend is Friday, June 13th. Thermo Fisher Scientific's dividend payout ratio is presently 10.09%.

Wall Street Analyst Weigh In

TMO has been the subject of a number of research reports. Argus lowered their price target on Thermo Fisher Scientific from $620.00 to $470.00 and set a "buy" rating for the company in a report on Tuesday, April 29th. Barclays cut their price target on Thermo Fisher Scientific from $620.00 to $475.00 and set an "equal weight" rating on the stock in a research note on Thursday, April 10th. Evercore ISI lowered their price objective on shares of Thermo Fisher Scientific from $585.00 to $500.00 and set an "outperform" rating for the company in a research note on Thursday, April 24th. Citigroup reduced their price target on shares of Thermo Fisher Scientific from $650.00 to $570.00 and set a "neutral" rating for the company in a report on Tuesday, March 4th. Finally, Robert W. Baird dropped their price objective on shares of Thermo Fisher Scientific from $603.00 to $573.00 and set an "outperform" rating on the stock in a research note on Thursday, April 24th. Four equities research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. According to MarketBeat, Thermo Fisher Scientific currently has an average rating of "Moderate Buy" and a consensus target price of $605.30.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, SVP Michael A. Boxer sold 3,775 shares of the business's stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $532.52, for a total value of $2,010,263.00. Following the completion of the transaction, the senior vice president now owns 10,816 shares of the company's stock, valued at $5,759,736.32. The trade was a 25.87% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Gianluca Pettiti sold 300 shares of the firm's stock in a transaction dated Monday, April 28th. The stock was sold at an average price of $429.93, for a total value of $128,979.00. Following the sale, the executive vice president now directly owns 23,167 shares in the company, valued at approximately $9,960,188.31. This trade represents a 1.28% decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 0.33% of the company's stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.